10-K: Omada Health Reports Strong Revenue Growth, Reduced Losses

Omada Health, a virtual care provider, announced a significant increase in revenue and a substantial reduction in net losses for the fiscal year ended December 31, 2025, driven by member growth and operational efficiencies.

Summary

• Total revenue increased by 53% to $260.2 million for the year ended December 31, 2025, compared to $169.8 million in 2024.
• Net loss significantly decreased to $12.8 million in 2025, down from $47.1 million in 2024 and $67.5 million in 2023.
• Gross profit rose by 66% to $170.9 million in 2025, with gross margin expanding by 5.1 percentage points to 65.7%.
• Total members enrolled in Omada's virtual care programs grew to 886,000 as of December 31, 2025, a 55% increase from 2024.
• The company completed its Initial Public Offering (IPO) on June 9, 2025, raising net proceeds of $151.6 million.
• All outstanding debt facilities (MidCap Term Facility and Revolving Facility) were fully repaid on July 31, 2025, using IPO proceeds.
• Omada continues to invest in its multi-condition platform, including cardiometabolic programs (diabetes prevention, diabetes, hypertension, high cholesterol) and musculoskeletal (MSK) conditions.
• The GLP-1 Care Track, launched in 2023, supports over 150,000 members on GLP-1 therapies, with plans to offer prescribing capabilities for GLP-1s and other anti-obesity medications (AOMs) later this year.
• A material weakness in internal control over financial reporting related to inadequate formalized processes and control activities for financial close and reporting remains as of December 31, 2025, though two other material weaknesses were remediated.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighting significant financial improvements, robust member growth, and strategic expansion into high-demand areas like GLP-1 support, despite ongoing net losses and internal control challenges.

Positives

• Total revenue increased by 53% year-over-year to $260.2 million in 2025, indicating strong business growth.
• Net loss decreased substantially from $47.1 million in 2024 to $12.8 million in 2025, showing improved financial performance and a path towards profitability.
• Gross margin expanded by 5.1 percentage points to 65.7% in 2025, reflecting increased Care Team efficiency and expanded use of supporting technologies.
• Total members grew by 55% to 886,000 as of December 31, 2025, demonstrating strong market acceptance and enrollment.
• Operating activities generated positive cash flow of $18.3 million in 2025, a significant improvement from negative cash flows in prior years.
• The successful IPO in June 2025 raised $151.6 million in net proceeds, strengthening the company's liquidity.
• All outstanding debt facilities were fully repaid in July 2025, reducing financial leverage and interest expense.
• High customer retention rate of over 90% and customer satisfaction rate of over 90% as of December 31, 2025, indicate strong relationships and service quality.
• Demonstrated clinical outcomes for cardiometabolic programs, including sustained weight loss and reductions in A1C and blood pressure, supported by 30 published, peer-reviewed studies.
• Introduction of GLP-1 Care Tracks and future prescribing capabilities for GLP-1s and other AOMs addresses an evolving and high-demand market segment.

Negatives

• The company has a history of net losses since inception, with an accumulated deficit of $456.7 million as of December 31, 2025.
• A material weakness in internal control over financial reporting related to inadequate formalized processes and control activities for financial close and reporting remains as of December 31, 2025.
• A substantial portion of sales (77% in 2025) comes from or through a limited number of customers and channel partners, with two Cigna Group affiliates accounting for 32% and 33% of revenue in 2025, posing concentration risk.
• The market for virtual care programs is new, rapidly evolving, and highly competitive, making demand difficult to forecast.
• The company incurs significant upfront costs in establishing and expanding relationships with customers and channel partners, and in acquiring and enrolling members, which may not always be recovered.
• Reliance on a limited number of third-party suppliers for devices and cellular connectivity, and external partners for complementary healthcare services, introduces supply chain and operational risks.
• The market price of common stock has been volatile since its IPO, declining from $100.00 on June 6, 2025, to $68.61 on December 31, 2025.

Risks

• Limited operating history and challenges in managing rapid growth effectively.
• Inability to consistently achieve or maintain profitability in the future, given a history of net losses and expected increases in operating expenses.
• Failure of programs to achieve and maintain market acceptance, potentially leading to sales below expectations.
• Intense and rapidly evolving competition from digital health companies, large technology companies, and traditional healthcare providers, some with greater resources.
• Competitive solutions or technological breakthroughs (e.g., new drugs, AI advancements) could adversely affect demand for Omada's programs.
• Programs may result in member harm or injury, leading to liability claims and reputational damage.
• Reliance on the growth and success of customers and channel partners (health plans, PBMs) and unpredictable member enrollment, which are affected by factors outside of Omada's control.
• Decrease in the number of individuals covered by customers or channel partners, or a reduction in the number of programs they cover, could lead to declining member enrollment and revenue.
• Failure to achieve and maintain meaningful member engagement, clinical outcomes, and/or cost savings could result in repayment obligations under performance guarantees and reduced revenue.
• Significant upfront costs in establishing and expanding customer/channel partner relationships and member acquisition may not be recovered if relationships are not maintained or engagement is low.
• Disruption of service at third-party data centers and hosting providers (e.g., AWS) or SaaS companies could interrupt program delivery and harm business.
• Dependence on a limited number of third-party suppliers for devices, supplies, cellular connectivity, and external partners for healthcare services (e.g., prescriptions), with potential for supply chain disruptions or quality failures.
• Seasonality in business operations, with fluctuations in sales and enrollment rates, leading to variability in financial results.
• Cybersecurity incidents, data breaches, and other disruptions to IT systems could compromise confidential information, expose Omada to liability, and harm reputation.
• Operating in a highly regulated industry, with changes in healthcare laws, medical device regulations (FDA), and data privacy/security laws (HIPAA, CCPA) potentially increasing costs or restricting operations.
• Potential for software applications to become subject to extensive FDA medical device regulatory requirements if enforcement policies change or if automated diagnoses are perceived.
• Dependence on relationships with affiliated professional entities (e.g., PPTG) for physical therapy and medical services, with risks if these relationships are disrupted or found to violate state corporate practice of licensed professions or fee-splitting laws.
• Exposure to medical liability claims, which may exceed insurance coverage.
• Risks from legal and arbitration proceedings, including product liability, intellectual property infringement, employment matters, and/or alleged violations of other applicable laws.
• Failure to comply with the FCPA, economic and trade sanctions regulations, and similar laws could subject the company to penalties and other adverse consequences.
• Changes in the regulation of the Internet could adversely affect business.
• Legislative or regulatory healthcare reforms or reductions in government spending may make it more difficult and costly to produce, market, and distribute programs profitably.
• Subject to consumer protection laws that regulate marketing and benefit outreach practices and prohibit unfair or deceptive acts or practices.
• Certain devices and supplies provided in connection with programs are subject to extensive government regulation, and any failure by producers to comply could harm business.
• Business could be adversely affected by legal challenges to its business model or by actions restricting its ability to provide the full range of services in certain jurisdictions.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to certain provisions of the Internal Revenue Code or state tax law.
• Effective tax rate may vary significantly from period to period due to various internal and external factors.
• Applicability of sales, use, and other tax laws or regulations on the business is uncertain, potentially leading to additional tax liability.
• Cash deposits with financial institutions exceed insured limits, posing a risk in the event of bank failure.
• Changes in accounting principles or the interpretation thereof by the Financial Accounting Standards Board (FASB) affecting consolidation of entities could impact consolidation of total revenues derived from PPTG.
• As an emerging growth company, reduced reporting requirements may make common stock less attractive to investors.
• Increased costs and additional regulations as a result of recently becoming a public company.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
• Claims for indemnification by directors, officers, and other employees or agents may reduce available funds.
• Choice of forum provisions could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• The market price of common stock may be volatile, which could cause the value of investment to decline.
• If securities or industry analysts do not continue to publish research or reports, or if they issue an adverse or misleading opinion, stock price and trading volume could decline.
• Engaging in acquisitions or strategic transactions or partnerships may increase capital requirements, dilute stockholders, cause debt, or subject the company to other risks.
• Economic uncertainties or downturns in the general economy or the industries in which the company or its customers/channel partners operate could disproportionately affect demand for programs.

Future Outlook

Omada Health expects continued long-term growth in its core business, driven by expanding its customer and channel partner base, increasing multi-program adoption within existing customers, and improving member enrollment and engagement. The company plans selective investments in platform, programs, and operations, including responding to customer needs organically or through partnerships/acquisitions. The GLP-1 therapeutic space is rapidly evolving, and Omada anticipates continued demand for its GLP-1 companion programs and prescribing offerings, aiming to enhance medication effectiveness and durability while managing costs. The company also expects to experience seasonality in its business, with higher sales in late spring/early fall and higher enrollment in the first and second quarters.

Management Comments

• Our mission is to bend the curve. Our hope is that, one day, tomorrows epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada.
• We strive to inspire and enable people to make lasting health changes on their own terms.
• We differentiate through our human-led, technology-enabled care model, which combines proactive Care Teams with data-driven tools to deliver personalized support at scale. We call this approach Compassionate Intelligence.
• We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates.
• We believe we compete effectively based on a combination of clinical rigor, differentiated care delivery, and a scalable go-to-market strategy.
• The significant overlap across these chronic conditions created a natural growth avenue by enabling a coordinated, context-informed care approach across conditions.
• With over 150,000 members across our programs having used GLP-1s as of December 31, 2025, Omada has demonstrated expertise in supporting members currently taking these therapies to make lasting health changes.
• We believe we are meeting this dynamic period in the GLP-1 market, aiming to enhance both the clinical impact of these therapies for our members and the economic benefits of GLP-1s.
• Our new prescribing capability, launching later this year, is designed to provide broad longitudinal medication support, from the time of the prescription through the duration of a members time taking an AOM.
• We believe human relationships and empathy are fundamental drivers of sustainable behavior change.
• We believe virtual care should be subject to many of the same quality control expectations as traditional in-person care.
• We believe platforms that combine clinical rigor, multi-condition reach, and evidence based, human-led care are well positioned to partner with employers, health plans, PBMs, and government programs.
• We further believe that advantage increasingly will accrue to organizations that can deliver additive value alongside powerful medications, provide consumer-grade experiences without sacrificing clinical integrity, and scale responsibly through trusted channels.
• We believe there remains a critical need to instill lasting behavior change in order to counter drawbacks like loss of muscle mass and maximize the benefits of these therapies.
• We believe that the breadth of our success is based in part on our diverse, customer-centric go-to-market strategy and our multi-condition approach.
• We believe that our customer satisfaction rates are strong and reflect the value of our services to customers.
• We believe that our future growth, success, and performance are dependent on many factors, including those set forth below.
• We believe there is substantial opportunity to further grow our base of customers and channel partners in our large addressable market.
• We believe that the ability to grow the share of revenue that we generate from existing customers is a key driver of long-term growth.
• We believe we are well positioned to respond to their requirements organically or, where appropriate, to add new capabilities through partnerships and potential acquisitions.
• We believe that current macroeconomic factors, including the impact of inflation and tariffs, are impacting customer and channel partner spending decisions.

Industry Context

StockSavvy.ai notes that Omada Health's strong revenue growth and reduced net losses align with the broader trend of increasing adoption of virtual care solutions, particularly for chronic disease management. The company's focus on cardiometabolic conditions and musculoskeletal health positions it well within a growing market driven by rising healthcare costs and demand for patient-centric, personalized care. The strategic expansion into GLP-1 therapy support and prescribing capabilities is a timely response to the significant impact of these medications on the obesity and diabetes markets, reflecting an industry shift towards integrated behavioral and pharmacological approaches. Omada's 'Compassionate Intelligence' model, combining human coaching with AI, is a key differentiator in a competitive landscape where clinical rigor and scalable, evidence-based care are increasingly valued by payers and employers. The high customer retention and satisfaction rates suggest effective execution in a market demanding demonstrable clinical outcomes and ROI.

Comparison to Industry Standards

• Omada's reported average weight loss of 16.3% for members on GLP-1s who engaged with the Enhanced GLP-1 Care Track for 12 months compares favorably to the 11.9% demonstrated in 'other real-world evidence' for GLP-1 users, suggesting superior outcomes when combined with Omada's behavioral support.
• The 0.8% weight regain for members who discontinued GLP-1s but stayed on the Enhanced GLP-1 Care Track, with 63.2% maintaining or continuing to lose weight at 12 months, indicates a strong ability to sustain results post-medication, a critical challenge in the broader weight management industry.
• Omada's 3-year average customer retention rate of over 90% and customer satisfaction rate of over 90% are strong indicators of performance, likely exceeding average retention and satisfaction rates for many digital health vendors in a competitive and evolving market, though specific industry benchmarks for direct comparison are not provided in the filing.
• The company's 30 published, peer-reviewed studies as of December 31, 2025, demonstrate a commitment to evidence-based care, which is a key competitive factor and likely positions Omada favorably against competitors who may have less robust clinical validation for their programs, such as Hello Heart Inc., Lark Technologies, Inc., Livongo (via Teladoc Health, Inc.), Onduo LLC, Vida Health, Inc., and Virta Health Corp. in cardiometabolic, or Hinge Health, Inc. and SWORD Health, Inc. in MSK.

Corporate Governance

Related Party Transactions

• Affiliates of The Cigna Group, which beneficially owns more than 5% of Omada Health's outstanding capital stock, are significant customers and channel partners.
• Two Cigna Group affiliates accounted for 32% and 33% of total revenue for the year ended December 31, 2025.
• Accounts receivable from a related party (Cigna affiliate) totaled $22.8 million as of December 31, 2025, and $13.2 million as of December 31, 2024.
• Prepaid expenses and other current assets include $0.3 million from a related party as of December 31, 2025.
• Accounts payable include $1.0 million from a related party as of December 31, 2025.
• Accrued expenses and other current liabilities include $4.9 million from a related party as of December 31, 2025.
• Deferred revenue includes $18.8 million from a related party as of December 31, 2025.
• Payments from Cigna Group affiliates to Omada Health were $157.6 million, $89.9 million, and $63.3 million for the years ended December 31, 2025, 2024, and 2023, respectively.
• Payments from Omada Health to Cigna Group affiliates were $23.4 million, $17.2 million, and $13.1 million for the years ended December 31, 2025, 2024, and 2023, respectively.

Stakeholder Impact

• **Shareholders**: Positive impact from significant revenue growth, reduced net losses, positive operating cash flow, and successful IPO. However, the remaining material weakness in internal controls and high customer concentration pose risks. The stock price has been volatile since IPO, declining from $100 to $68.61.
• **Employees**: The company's 'remote-first' culture, competitive compensation, benefits, and learning/development opportunities aim to attract and retain high-performing talent. The 2025 Incentive Award Plan and ESPP provide equity incentives. However, the need to scale Care Teams efficiently and potential unionization efforts are noted risks.
• **Customers (Employers, Health Plans, PBMs, Health Systems)**: Benefit from Omada's multi-condition virtual care platform, evidence-based programs, and high customer satisfaction/retention rates. The GLP-1 Care Tracks and prescribing capabilities offer new solutions for managing high-cost medications. High reliance on a few key partners (e.g., Cigna affiliates) means their business decisions significantly impact Omada.
• **Members**: Benefit from engaging, personalized, and integrated virtual care designed to improve health outcomes for chronic conditions. Access to dedicated health coaches, specialists, connected devices, and AI-powered tools. Potential negative reactions to requirements for GLP-1 program enrollment are noted.
• **Creditors**: The full repayment of the MidCap Term Facility and Revolving Facility significantly reduces the company's debt burden, improving its credit profile.

Next Steps

• Continue to hire qualified technical accounting and financial reporting personnel with public company experience to perform control activities.
• Continue the process of implementing, enhancing, and formalizing control activities related to significant accounts and disclosures.
• Invest in additional technology infrastructure and refinement to enhance monitoring of financial transactions and exceptions and to promote related data integrity.
• Launch prescribing capability for GLP-1 therapies and other anti-obesity medications later this year.
• First commercial launch of Omada for Cholesterol program expected in 2026, with broad launch planned for 2027.
• Expand the number of individuals covered for participation in programs by paying customers (covered lives).
• Improve enrollment effectiveness and drive sustained member engagement.
• Deepen relationships with employers, health plans, and pharmacy benefit managers.
• Expand distribution through a scalable, diversified go-to-market model.
• Convert eligible lives into active members through targeted enrollment outreach, multi-program adoption, and continued investment in technology.
• Monitor and respond to evolving regulatory frameworks for AI technologies.

Key Dates

Recommendation

Omada Health demonstrates strong operational momentum with significant revenue growth, expanding gross margins, and a substantial reduction in net losses, indicating a positive trajectory towards profitability. The successful IPO and debt repayment have significantly strengthened its balance sheet. The company's strategic focus on multi-condition virtual care, particularly its timely expansion into GLP-1 support, positions it well in a growing market. However, the stock has experienced considerable volatility since its IPO, declining from its initial trading price. The remaining material weakness in internal controls and high customer concentration, particularly with Cigna affiliates, present notable risks. While the underlying business performance is improving, the market's current valuation and the identified risks suggest a 'hold' recommendation, advising investors to monitor the effective remediation of internal control issues and diversification of customer base before considering further investment.

Keywords

Virtual Care, Digital Health, Chronic Disease Management, Diabetes Prevention, Weight Management, Hypertension, Musculoskeletal Health, GLP-1 Support, Artificial Intelligence in Healthcare, Telehealth, SEC Filing, 10-K, Healthcare Technology, Corporate Governance, Risk Management, Financial Performance, Omada Health